• Data is Both the Fuel and Downfall of AI in Drug Development

    May 27 | Diagnostics World News | At Scope X, Novo Nordisk gave a presentation on how high-impact opportunities for leveraging AI across the pharmaceutical R&D cycle are too numerous to count but won’t “automagically” solve any of the longstanding problems in ushering molecules to market. AI requires human attention to match tools to tasks for ensuring the accuracy of model predictions, and the pitfalls are dangerously easy to miss, More

  • Follow the Money: AI Engine for Drug Design, NVision Expands Platform, Kanvas Advances Partnerships

    May 26 | Diagnostics World News | Isomorphic Labs plans to continue development and deployment of its AI drug design engine; NVision expands POLARIS platform into quantum computation; Kanvas Biosciences advances commercial partnerships that leverage the company’s spatial imaging and manufacturing platform; and more. More

  • Pancreatic Cancer Detection Based on Circulating Tumor-Released Nanoparticles Beats Biopsy

    May 21 | Diagnostics World News | Researchers at the Oregon Health and Science University have established a rapid blood test to differentiate pancreatic cancer from other pancreatic conditions. The method involves the analysis of tumor-secreted nanoparticles on a specialized chip and actually outperforms the gold-standard needle-based biopsy diagnosis. More

  • Beyond the Snapshot: A Duke Researcher Is Using Blood Flow Simulations to Transform Heart Disease Diagnosis

    May 19 | Diagnostics World News | For patients seeing a cardiologist, their diagnosis and next steps rest on data gathered at a single point in time: the day of their appointment. One blood pressure reading. One imaging scan. One day’s data to define the health of a continuously changing system. The Duke Center for Computational and Digital Health Innovation developed a platform that may be a better way. More

  • Microchimerism: Lifelong Biological Connections Impacting Everyone

    May 14 | Diagnostics World News | During pregnancy, the cells of a fetus make their way into the tissues of mom where they can persist for decades, much like what happens when someone gets an organ transplant but to a far tinier extent. That the maternal-fetal exchange results in chimerism—more specifically, “microchimerism”—is a relatively little-known yet fascinating and profoundly common biological phenomenon. More

  • 23andMe: How Genetics Contribute to GLP-1 Drug Outcomes

    May 13 | Diagnostics World News | An engaged research cohort of over 11 million genotyped individuals has enabled 23andMe to produce a library of more than 300 peer-reviewed publications over the past 16 years. Following a 2025 bankruptcy filing, when it reemerged as a nonprofit medical research organization, the focus has settled on providing individuals with access to their genetic information, supporting genetics education, and studies that provide a deeper understanding of human genetics. More

  • Regulatory Outlook in Diagnostics Innovative and Uncertain

    May 12 | Diagnostics World News | The diagnostics industry is at the intersection of enormous clinical development and technological change, enabling first-ever detection milestones heavily driven by artificial intelligence (AI) and multi-biomarker tests. But it has increasingly been coming into conflict with a decades-old regulatory system that didn’t anticipate these technological changes and a political environment that favors U.S. competition and innovation but is also interested in cutting the budget. More

  • One Size Fits Few: Where Tailored AI Tools Outpace Generic Options

    May 07 | Diagnostics World News | There’s a seductive promise baked into the rise of large language models: that a single, powerful AI trained on the breadth of human knowledge can do virtually anything. Need to draft a contract? Summarize a research paper? Predict whether a drug molecule will cross the blood-brain barrier? Just ask GPT. But ask the executives building AI tools inside two highly specialized fields — radiology and early-stage drug discovery — and they’ll tell you that promise breaks down the moment you need answers that actually matter. More

  • Preeclampsia: Starting Point for Rethinking Hypertension

    May 05 | Diagnostics World | The diagnosis and management of hypertension is in a troublingly bleak state, despite myriad treatments and regular blood pressure checks in primary care settings intended to catch the condition early. The conundrum is rooted in a trio of problems that co-exist like “gears with broken teeth that don’t mesh together very well." More

  • Follow the Money: Discovery Service Expansion, AI-Driven Discovery of Cancer Targets, More

    Apr 30 | Diagnostics World | Alloy speeds up growth to deepen its core discovery service in antibodies, genetic medicines, and cell therapies; RyboDyn accelerates transition from foundational discovery into scaled platform execution and progresses early-stage programs into IND-enabling studies; and more. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more